AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10655529 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amylose maize starch (50 g per liter of oral rehydration solution)
Number of subjects: 48
Study 9288506 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair of descending thoracic aortic aneurysms with aortobronchial fistulae
Number of subjects: 145
Study 9288506 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair of descending thoracic aortic aneurysms with aortoesophageal fistulae
Number of subjects: 145
Study 9288506 — intervention group
Group type: COMPARATOR
Intervention: Repair of descending thoracic aortic aneurysms without fistulae
Number of subjects: 145
Study 9288506 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality at 30 days
Number of subjects: 145
Study 9288506 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraparesis and/or paraplegia
Number of subjects: 145
Study 8147243 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic Doxycycline (group 1)
Number of subjects: 300
Study 8147243 — intervention group
Group type: COMPARATOR
Intervention: No therapy (group 2)
Number of subjects: 300
Study 3539613 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (5-ISMN) 60 mg in a controlled release formulation (Durules) given once daily
Number of subjects: 24
Study 3539613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31806540 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg olaparib twice daily
Number of subjects: 98
Study 31806540 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg olaparib twice daily
Number of subjects: 98
Study 31806540 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (both doses)
Number of subjects: 98
Study 31248918 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gabapentin (300‐2700 mg)
Number of subjects: 12
Study 31248918 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 12
Study 31248918 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin and placebo
Number of subjects: 12
Study 28572159 — intervention group
Group type: EXPERIMENTAL
Intervention: APOL1 high-risk variants (2 risk variants)
Number of subjects: 693
Study 28572159 — intervention group
Group type: COMPARATOR
Intervention: APOL1 low-risk variants (0-1 risk variant)
Number of subjects: 693
Study 25599193 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 1410
Study 25599193 — intervention group
Group type: COMPARATOR
Intervention: Control group (low aerobic exercise)
Number of subjects: 1410
Study 23725939 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hands-on training simulation and 20-minute multimedia presentation
Number of subjects: 53
Study 23725939 — intervention group
Group type: COMPARATOR
Intervention: Hands-on training simulation alone
Number of subjects: 53
Study 21533568 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive integrated intervention
Number of subjects: 210
Study 21533568 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 210
Study 18082500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 18082500 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose MCC-135
Number of subjects: 141
Study 18082500 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose MCC-135
Number of subjects: 141
Study 16530377 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative patient education (special educational session and tour of the cardiac surgery unit)
Number of subjects: 110
Study 16530377 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital protocol (no preoperative education or tour)
Number of subjects: 110
Study 12742838 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide hydrochloride (Trusopt 2% eye drops)
Number of subjects: 20
Study 12742838 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (saline placebo)
Number of subjects: 20
Study 12742838 — intervention group
Group type: COMPARATOR
Intervention: Carrier placebo (solution identical to the carrier substance of dorzolamide)
Number of subjects: 20
Study 11044264 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (Poly Vi‐Sol with iron) three times per week
Number of subjects: 207
Study 11044264 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation with SP treatment
Number of subjects: 207
Study 11044264 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation without SP treatment
Number of subjects: 207
Study 11044264 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 207
Study 8615485 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 40
Study 8615485 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PCB)
Number of subjects: 40
Study 1576052 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg codeine phosphate
Number of subjects: 6
Study 1576052 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg propantheline bromide
Number of subjects: 6
Study 1576052 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide monohydrochloride
Number of subjects: 6
Study 1576052 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 6
Study 1576052 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens (codeine, propantheline, metoclopramide)
Number of subjects: 6
Study 6591216 — intervention group
Group type: EXPERIMENTAL
Intervention: nortriptyline
Number of subjects: 12
Study 6591216 — intervention group
Group type: EXPERIMENTAL
Intervention: femoxetine
Number of subjects: 12
Study 6591216 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 12
Study 6591216 — intervention group
Group type: COMPARATOR
Intervention: citalopram
Number of subjects: 12
Study 6591216 — intervention group
Group type: COMPARATOR
Intervention: cis-flupenthixol
Number of subjects: 12
Study 6591216 — intervention group
Group type: COMPARATOR
Intervention: trans-flupenthixol
Number of subjects: 12
Study 6591216 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 31370913 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 0
Study 31370913 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30203006 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 10854
Study 30203006 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10854
Study 25980843 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg
Number of subjects: 48
Study 25980843 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 48
Study 23431958 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ivermectin 200 µg/kg body weight
Number of subjects: 320
Study 23431958 — intervention group
Group type: COMPARATOR
Intervention: Crotamiton 10% cream applied twice daily for five consecutive days
Number of subjects: 320
Study 22516832 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 254
Study 22516832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 20472503 — intervention group
Group type: EXPERIMENTAL
Intervention: recHCG (250 microg)
Number of subjects: 30
Study 20472503 — intervention group
Group type: COMPARATOR
Intervention: uHCG (10,000 IU)
Number of subjects: 30
Study 18042502 — intervention group
Group type: EXPERIMENTAL
Intervention: fosamprenavir (FPV) with ritonavir (FPV/r)
Number of subjects: 700
Study 16220584 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Abdominal Hysterectomy (TAH)
Number of subjects: 319
Study 16220584 — intervention group
Group type: COMPARATOR
Intervention: Subtotal Abdominal Hysterectomy (SAH)
Number of subjects: 319
Study 16220584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TAH and SAH
Number of subjects: 319
Study 16220584 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinent women
Number of subjects: 319
Study 12116072 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component behavioral intervention (educational intervention)
Number of subjects: 272
Study 12116072 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 272
Study 12577414 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-GSP (Radiotherapy combined with Ginseng polysaccharide injection)
Number of subjects: 131
Study 12577414 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control group)
Number of subjects: 131
Study 12577414 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-GSP
Number of subjects: 131
Study 9442148 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (nonionic dimer)
Number of subjects: 64
Study 9442148 — intervention group
Group type: COMPARATOR
Intervention: Iopromide (nonionic monomer)
Number of subjects: 64
Study 9442148 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 64
Study 8156571 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary endarterectomy
Number of subjects: 0
Study 8156571 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery using only bypasses
Number of subjects: 0
Study 3063783 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (diazide‐hydrochlorothiazide with triamterene +/‐ methyldopa)
Number of subjects: 120
Study 3063783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30139780 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg subcutaneously every 8 weeks (Q8W, first three doses every 4 weeks (Q4W))
Number of subjects: 0
Study 30139780 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg subcutaneously every 4 weeks (Q4W)
Number of subjects: 0
Study 30139780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28031704 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA unit care
Number of subjects: 408
Study 28031704 — intervention group
Group type: COMPARATOR
Intervention: Conventional acute medical care
Number of subjects: 408
Study 26336957 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin (10/20 mg)
Number of subjects: 1128
Study 26336957 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin (10 mg, 20 mg)
Number of subjects: 1128
Study 24565342 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway Supreme(®) (LMAS)
Number of subjects: 60
Study 24565342 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 60
Study 21779784 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 190
Study 21779784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 18626722 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with serious mental illness (SMI)
Number of subjects: 24016
Study 18626722 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with depression
Number of subjects: 24016
Study 18626722 — intervention group
Group type: COMPARATOR
Intervention: Patients without SMI or depression (Control)
Number of subjects: 24016
Study 16528523 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphonylurea drugs (SU group)
Number of subjects: 42
Study 16528523 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 12892606 — intervention group
Group type: EXPERIMENTAL
Intervention: SRK‐T formula
Number of subjects: 86
Study 12892606 — intervention group
Group type: COMPARATOR
Intervention: SRK‐II formula
Number of subjects: 86
Study 12892606 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SRK‐T and SRK‐II
Number of subjects: 86
Study 12892606 — intervention group
Group type: COMPARATOR
Intervention: K-readings at 39.00 D, 41.00 D, 45.00 D, or 47.00 D
Number of subjects: 86
Study 12892606 — intervention group
Group type: COMPARATOR
Intervention: K-reading at 43.00 D
Number of subjects: 86
Study 12892606 — intervention group
Group type: COMPARATOR
Intervention: Axial lengths
Number of subjects: 86
Study 12892606 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 86
Study 11155900 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI) therapy
Number of subjects: 70
Study 11155900 — intervention group
Group type: EXPERIMENTAL
Intervention: Second PI regimen after treatment failure
Number of subjects: 70
Study 8646821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ethanol (0.3 gm/kg)
Number of subjects: 12
Study 1466216 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms of epidural clonidine
Number of subjects: 0
Study 1466216 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms of epidural clonidine
Number of subjects: 0
Study 1466216 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of parenteral morphine
Number of subjects: 0
Study 30679379 — intervention group
Group type: EXPERIMENTAL
Intervention: theory‐based, culturally tailored video
Number of subjects: 215
Study 30679379 — intervention group
Group type: COMPARATOR
Intervention: usual‐care mainstream video
Number of subjects: 215
Study 29562556 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT) of the lower extremities
Number of subjects: 90
Study 29562556 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance and Motor Control Training (BMCT) that challenges gait function
Number of subjects: 90
Study 29562556 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 90
Study 28007025 — intervention group
Group type: EXPERIMENTAL
Intervention: XELIRI with or without bevacizumab (7.5 mg/kg on day 1), repeated every 3 weeks
Number of subjects: 600
Study 28007025 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI with or without bevacizumab (5 mg/kg on day 1), repeated every 2 weeks
Number of subjects: 600
Study 24796937 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoreduced red blood cell (RBC) transfusion
Number of subjects: 84
Study 24796937 — intervention group
Group type: COMPARATOR
Intervention: No transfusion (control group)
Number of subjects: 84
Study 22705093 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO+WS (50 g isomaltulose + 21 g whey/soy)
Number of subjects: 30
Study 22705093 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO+C (50 g isomaltulose + 21 g casein)
Number of subjects: 30
Study 22705093 — intervention group
Group type: COMPARATOR
Intervention: ISO (50 g isomaltulose)
Number of subjects: 30
Study 21444695 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (8 mg/kg of body weight)
Number of subjects: 15
Study 21444695 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (standard-of-care antibiotic)
Number of subjects: 15
Study 17924898 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 30
Study 17924898 — intervention group
Group type: EXPERIMENTAL
Intervention: McCoy
Number of subjects: 30
Study 17924898 — intervention group
Group type: EXPERIMENTAL
Intervention: ILMA
Number of subjects: 30
Study 17924898 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 30
Study 16214624 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured telephone call
Number of subjects: 150
Study 16214624 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention-only telephone call
Number of subjects: 150
Study 16214624 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 12169147 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HT)
Number of subjects: 64
Study 12169147 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan
Number of subjects: 64
Study 12169147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 10199444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg intravenously followed by oral therapy for 5 days
Number of subjects: 301
Study 10199444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg intravenously plus dexamethasone before cisplatin and twice daily thereafter
Number of subjects: 301
Study 10199444 — intervention group
Group type: COMPARATOR
Intervention: High-dose metoclopramide (2 mg/kg) combined with clemastine, dexamethasone, and lorazepam
Number of subjects: 301
Study 10199444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg intravenously plus dexamethasone
Number of subjects: 301
Study 10199444 — intervention group
Group type: COMPARATOR
Intervention: High-dose metoclopramide cocktail
Number of subjects: 301
Study 8849290 — intervention group
Group type: EXPERIMENTAL
Intervention: CI 5-FU 450 mg/body/day + IVB LV 30 mg/body q wk (schedule A)
Number of subjects: 36
Study 8849290 — intervention group
Group type: EXPERIMENTAL
Intervention: CI 5-FU 200 mg/m2/day + IVB LV 20 mg/m2 q wk (schedule B)
Number of subjects: 36
Study 8849290 — intervention group
Group type: COMPARATOR
Intervention: Inpatient chemotherapy (5-FU + CDDP)
Number of subjects: 36
Study 8849290 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral UFT (400-600 mg/day) after chemotherapy
Number of subjects: 36
Study 1980218 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (10 ml, 0.1 mg/ml)
Number of subjects: 105
Study 1980218 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 ml vehicle alone)
Number of subjects: 105
Study 6768088 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 8
Study 6768088 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 8
Study 31889356 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (2018)
Number of subjects: 1000
Study 31889356 — intervention group
Group type: COMPARATOR
Intervention: Group A (2017)
Number of subjects: 1000
Study 31889356 — intervention group
Group type: COMPARATOR
Intervention: Group A (2017) non-trauma patients
Number of subjects: 1000
Study 31465100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg/0.05 mL)
Number of subjects: 463
Study 31465100 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg/0.05 mL)
Number of subjects: 463
Study 31465100 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg/0.05 mL)
Number of subjects: 463
Study 28335413 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitin Oligosaccharide (COS) 20 mg with half-dose antibiotics
Number of subjects: 312
Study 28335413 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - one-gram alternative antibiotics
Number of subjects: 312
Study 28335413 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PG) - 20 mg placebo with half-dose antibiotics
Number of subjects: 312
Study 26110441 — intervention group
Group type: COMPARATOR
Intervention: DTSNB (Distal Transsartorial Saphenous Nerve Block)
Number of subjects: 120
Study 26110441 — intervention group
Group type: EXPERIMENTAL
Intervention: ACSNB (Adductor Canal Saphenous Nerve Block)
Number of subjects: 120
Study 25603664 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipelle endometrial sampling
Number of subjects: 203
Study 25603664 — intervention group
Group type: COMPARATOR
Intervention: Dilatation and curettage (D&C)
Number of subjects: 203
Study 22225530 — intervention group
Group type: EXPERIMENTAL
Intervention: superelastic NiTi Begg
Number of subjects: 96
Study 22225530 — intervention group
Group type: COMPARATOR
Intervention: superelastic NiTi PEA
Number of subjects: 96
Study 22225530 — intervention group
Group type: COMPARATOR
Intervention: multistranded (coaxial) stainless steel Begg
Number of subjects: 96
Study 19458139 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 24
Study 19458139 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2
Number of subjects: 24
Study 19458139 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 24
Study 19458139 — intervention group
Group type: COMPARATOR
Intervention: Testosterone
Number of subjects: 24
Study 19458139 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine
Number of subjects: 24
Study 17766659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaspargase (Oncaspar) at a dose of 2,500 IU/m(2) administered i.m. on day 3 of the 4-week induction phase and on day 3 of each of two 8-week delayed intensification phases
Number of subjects: 118
Study 17766659 — intervention group
Group type: COMPARATOR
Intervention: Native Escherichia coli asparaginase (Elspar) at a dose of 6,000 IU/m(2) administered i.m. three times weekly for nine doses during induction and for six doses during each delayed intensification phase
Number of subjects: 118
Study 17766659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaspargase (Oncaspar)
Number of subjects: 118
Study 17766659 — intervention group
Group type: COMPARATOR
Intervention: Native Escherichia coli asparaginase (Elspar)
Number of subjects: 118
Study 17766659 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Pegaspargase and Native Escherichia coli asparaginase
Number of subjects: 118
Study 15292333 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose GH (1.7 microg/kg.d)
Number of subjects: 12
Study 15292333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11208838 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant postoperative radiotherapy (Arm A)
Number of subjects: 488
Study 11208838 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy plus concurrent chemotherapy (Arm B)
Number of subjects: 488
Study 11208838 — intervention group
Group type: EXPERIMENTAL
Intervention: Wildtype K-ras
Number of subjects: 488
Study 11208838 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutant K-ras randomized to chemotherapy plus radiotherapy
Number of subjects: 488
Study 11208838 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 mutations and protein overexpression
Number of subjects: 488
Study 11208838 — intervention group
Group type: EXPERIMENTAL
Intervention: K-ras mutations
Number of subjects: 488
Study 9635312 — intervention group
Group type: EXPERIMENTAL
Intervention: Bur preparation with a 1/4-round bur in a low-speed handpiece and acid etching
Number of subjects: 72
Study 9635312 — intervention group
Group type: COMPARATOR
Intervention: Conventional preparation (pumicing and acid etching with 37% phosphoric acid)
Number of subjects: 72
Study 9635312 — intervention group
Group type: COMPARATOR
Intervention: High-speed microabrasion using 50 mu alpha alumina particles in a KCP 2000 machine
Number of subjects: 72